Huakang Biomedical Holdings Co Ltd

HKSE:08622 (China)  
HK$ 0.10 (-3%) May 27
At Loss
P/B:
0.75
Market Cap:
HK$ 48.55M ($ 6.22M)
Enterprise V:
HK$ 19.51M ($ 2.50M)
Volume:
144.00K
Avg Vol (2M):
1.86M
Warning! GuruFocus detected 3 Severe warning signs with 08622. Try a 7-Day Free Trial to check it out.
Volume:
144.00K
Market Cap HK$:
48.55M
Market Cap $:
6.22M
At Loss
Avg Vol (2M):
1.86M
Enterprise Value HK$:
19.51M
Enterprise Value $:
2.50M
PB Ratio:
0.75
Alerts Website Sources Stock PDF
Dataset
Financial Download P Manual of Stocksâ„¢

Business Description

Huakang Biomedical Holdings Co Ltd

ISIN : KYG4644W1069
http://www.szhuakang.com
No.16 Yinkui Road, 1-3 floor, Building D, Shenzhen Junxuan, Kui Xin Community, Kui Chong Office, Dapeng New District, Shenzhen, CHN
Compare
Compare
HKSE:00911HKSE:00858HKSE:01889HKSE:01312HKSE:01011ZTSXTER:MRKTSE:4502LSE:HLNNSE:SUNPHARMATSE:4523TSE:4507SZSE:000538XSWX:SDZHKSE:03692NSE:DIVISLABBOM:500124VTRSNBIXSZSE:000963
Traded in other countries / regions
08622.Hong Kong
IPO Date
2018-12-13
Description
Huakang Biomedical Holdings Co Ltd is engaged in the research, development, manufacture, marketing, and sale of in-vitro diagnostic reagents and auxiliary reproductive supplies and equipment in China. Its products include Male fertility IVD reagents; Parasite antibody detection reagents; EBV antibody detection reagents; and Auxiliary reproductive supplies and equipment. The group has also diversified its business to vitamins and supplements products for the markets in the PRC, Hong Kong, and overseas.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 6.41
Equity-to-Asset 0.78
Debt-to-Equity 0.1
Debt-to-EBITDA -0.9
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.56
Distress
Grey
Safe
Beneish M-Score -3.36
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 33.7
3-Year EPS without NRI Growth Rate 24.6
3-Year FCF Growth Rate 39.4
3-Year Book Growth Rate -10.1

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 47.47
9-Day RSI 49.2
14-Day RSI 46.43
6-1 Month Momentum % -7.02
12-1 Month Momentum % -48.29

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.08
Quick Ratio 3.82
Cash Ratio 2.51
Days Inventory 142.18
Days Sales Outstanding 146.92
Days Payable 35.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.5
Shareholder Yield % -3.97

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % 65.36
Operating Margin % -27.22
Net Margin % -23.37
FCF Margin % -6.27
ROE % -10.61
ROA % -8.8
ROIC % -24.55
ROC (Joel Greenblatt) % -37.13
ROCE % -10.43
Years of Profitability over Past 10-Year 2

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.49
PB Ratio 0.75
Price-to-Tangible-Book 0.75
EV-to-EBIT -3.11
EV-to-EBITDA -3.11
EV-to-Revenue 0.72
EV-to-FCF -11.5
Price-to-Projected-FCF 4.85
Price-to-Net-Current-Asset-Value 0.97
Price-to-Net-Cash 1.94
Earnings Yield (Greenblatt) % -32.15
FCF Yield % -3.49

Financials

HKSE:08622's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Huakang Biomedical Holdings Co Ltd Executives

Details

GF Value: HK$0.16

HKSE:08622

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil HK$) 27.067
EPS (TTM) (HK$) -0.016
Beta -0.38
Volatility % 53.75
14-Day RSI 46.43
14-Day ATR (HK$) 0.004009
20-Day SMA (HK$) 0.09825
12-1 Month Momentum % -48.29
52-Week Range (HK$) 0.09 - 0.214
Shares Outstanding (Mil) 500.47

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Huakang Biomedical Holdings Co Ltd Filings

Filing Date Document Date Form
No Filing Data

Huakang Biomedical Holdings Co Ltd Stock Events

Financials Calendars
Event Date Price(HK$)
No Event Data

Huakang Biomedical Holdings Co Ltd Frequently Asked Questions

What is Huakang Biomedical Holdings Co Ltd(HKSE:08622)'s stock price today?
The current price of HKSE:08622 is HK$0.10. The 52 week high of HKSE:08622 is HK$0.21 and 52 week low is HK$0.09.
When is next earnings date of Huakang Biomedical Holdings Co Ltd(HKSE:08622)?
The next earnings date of Huakang Biomedical Holdings Co Ltd(HKSE:08622) is .
Does Huakang Biomedical Holdings Co Ltd(HKSE:08622) pay dividends? If so, how much?
Huakang Biomedical Holdings Co Ltd(HKSE:08622) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.